CUSIP: 15117P102
Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
4,257,982
-
Share change
-
-161,706
-
Total reported value
-
$67,344,065
-
Price per share
-
$15.82
-
Number of holders
-
40
-
Value change
-
-$2,568,233
-
Number of buys
-
13
-
Number of sells
-
21
Quarterly Holders Quick Answers
What is CUSIP 15117P102?
CUSIP 15117P102 identifies CBMG - CELLULAR BIOMEDICINE GROUP I - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2020
-
Previous quarter:
Q4 2019
Recent filing periods for CUSIP 15117P102:
Institutional Holders of CELLULAR BIOMEDICINE GROUP I - COM NEW (CBMG) as of Q1 2020
As of 31 Mar 2020,
CELLULAR BIOMEDICINE GROUP I - COM NEW (CBMG) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,257,982 shares.
The largest 10 holders included
BlackRock Inc., PLATINUM INVESTMENT MANAGEMENT LTD, Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., ARK Investment Management LLC, HILLHOUSE CAPITAL ADVISORS, LTD., STATE STREET CORP, VANGUARD GROUP INC, NORTHERN TRUST CORP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
40
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.